Inovio Pharmaceuticals

Inovio Pharmaceuticals announced pricing for a public offering of 12.5 million common shares and accompanying Series A warrants to purchase up to 12.5 million shares, or pre-funded warrants in lieu of the shares.

Inovio said it will release its first-quarter 2026 financial results after market close on May 13, 2026, followed by a conference call and webcast at 4:30 p.m. ET.

Inovio announced plans to participate in scientific conferences, including the American Society of Gene and Cell Therapy Annual Meeting in Boston, where it will present a poster on Factor VIII gene transfer in hemophilia A mice.

The FDA is reviewing the BLA for INO-3107 under its accelerated approval program, with a target PDUFA date of October 30, 2026. Commercial readiness plans are advancing in anticipation of a potential launch for treating adults with recurrent respiratory papillomatosis.

Inovio Pharmaceuticals, Inc. is an equal employment opportunity employer and lists career opportunities.

The page lists contact details for Inovio's general, investor relations, media, business development, clinical trials, medical affairs, and purchase order inquiries, along with addresses for its headquarters and device engineering and manufacturing facility.

Inovio is a biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. Its platform is designed to enable the body's cells to produce proteins that target disease.

Inovio Pharmaceuticals, Inc. collects information from website users, subscribers, and customers. Its privacy statement describes the types of information collected and how it is used to provide services.